The global blood screening market is expected to reach a value of USD 3.9
billion by 2024, based on a new report by Grand View Research, Inc. The growth
of the market is attributed to the increasing screening of donor and continuous
technological advancements by the market players. Demand for blood screening
tests are increasing continuously due to increasing donation, rising awareness
about transfusion-transmitted diseases, and technological developments in the
industry.
Thorough screening is necessary for all donated blood to ensure that
recipients receive the safest products. As of 2015, such testing consists of
screening for red cell antibodies, and the infectious diseases agents: HIV-1,
HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus
(HTLV) T. Cruzi, and T. pallidum (syphilis). Result of all these assays must be
negative for blood donation.
 |
| U.S. blood screening market by product, 2013 - 2024 (USD Million) |
Technological developments in the market increase the sensitivity and
efficiency of the tests. For instance, in 2016, the U.S. FDA approved the
Procleix Zika virus assay from Hologic, Inc. and Grifols to screen donated
blood. Furthermore, the U.S. FDA approved next-generation sequencing (NGS)
technology in 2013. The technology is cheaper and faster than previous DNA
analysis methods.
In depth research report on Blood Screening
Market
Further Key Findings from the Study Suggest:
·
Nucleic acid
amplification test or nucleic acid test (NAT) is expected to be the fastest
growing segment during the forecast period. It comprises transcription mediated
amplification (TMA) tests and polymerase chain reaction. Increasing demand of
NAT over ELISA test due to high sensitivity and specificity for viral nucleic
acid is contributing to the fastest growth during the forecast period.
·
In 2015,
reagent dominated the product segment. Introduction of new assays for the
detection of various diseases is expected to enable the segment to gain the
maximum share of market in the coming years. For instance, in January 2015 the
FDA approved Roche’s blood screening assay COBAS TaqScreen MPX Test for the
detection and identification of HCV, HIV, and HBV.
·
In 2015,
regionally North America dominated with a revenue share of more than 40%.
Government initiatives, presence of major players, and more patient
affordability are the major factors that contributed toward its dominance.
·
In August
2016, the FDA recommended the testing of all the donated blood in the U.S. and
its territories for Zika virus in order to prevent transmission of this virus
through the blood supply.
·
Asia Pacific
is expected to be the fastest growing region due to increasing investment of
industry players, government initiatives, and rising awareness about
transmission of diseases during its transfusion.
·
The Red Cross
in Japan entered into a contract with Grifols for nucleic acid testing (NAT)
for a blood donation camp in Japan in 2014. This agreement is anticipated to
propel the NAT market during the forecast period. However, low donation as
compared to requirement and high cost of kits and instruments are likely to
restrain the growth in low-income countries during the forecast period.
Grand View Research has segmented the blood screening market by
technology, product and region:
Blood Screening Market Technology Outlook
(Market Revenue in USD Million, 2013 - 2024)
·
Nucleic Acid
Amplification Test (NAT)
·
ELISA
·
Chemiluminescence
Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
·
Next-Generation
Sequencing (NGS)
·
Western
Blotting
Blood Screening Market Product Outlook (Market
Revenue in USD Million, 2013 - 2024)
·
Reagent
·
Instrument
Blood Screening Market Regional Outlook
(Market Revenue in USD Million, 2013 - 2024)
·
North America
o
U.S.
o
Canada
·
Europe
o
UK
o
Germany
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
·
Middle East
and Africa
o
South Africa
Browse more research reports of this category:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting
company, registered in the State of California and headquartered in San
Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, the company offers market intelligence studies ensuring
relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
For more market analysis reports, please
visit: http://www.grandviewresearch.com/
No comments:
Post a Comment